ANALYSIS OF CANAGLIFLOZIN, REVIEW
- تاريخ النشر: 2017-03-08
Canagliflozin, being a Sodium Glucose co-Transporter type 2 (SGLT2) Inhibitor, as a new class for treatment of Type 2 diabetes mellitus, offer a novel mechanism of action, which has been recently approved by USFDA for use in type 2 diabetes mellitus, either alone or in combination with other oral hypoglycaemic agents and insulin. The aim of this review firstly to focus on a comprehensive update of chromatography determination of Canagliflozin in bulk and in pharmaceutical preparations, In which has been described using TLC, HPLC/MS, RP-HPLC and UV methods. Secondly to localize the chromatographic conditions for separation and quantification. This review provides detailed information on separation conditions for Canagliflozin alone, with Metformin and in the presence of its degradation products.